<DOC>
	<DOCNO>NCT00002195</DOCNO>
	<brief_summary>The purpose study see safe effective add 141W94 anti-HIV regimen include retrovir plus epivir .</brief_summary>
	<brief_title>A Study Retrovir Epivir Alone Combination With 141W94 HIV-Infected Patients</brief_title>
	<detailed_description>This double-blind , placebo-controlled , two-arm study compare treatment triple regimen consist 141W94 , retrovir , epivir double regimen consist retrovir epivir .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIVpositive status . Screening viral load &gt; = 10,000 copies/mm3 14 day prior entry . CD4+ cell count &gt; = 200 cells/mm3 14 day prior entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinical diagnosis AIDS ( CDC 1993 Classification C ) . Concurrent Medication : Excluded : Terfenadine , astemizole , cisapride , triazolam , medazolam , ergotamine/dihydroergotaminecontaining regimen . Patients follow prior condition exclude : Clinically relevant hepatitis previous 6 month . Prior Medication : Excluded : Greater 4 week nucleoside antiretroviral therapy . Previous therapy HIV protease inhibitor . Cytotoxic chemotherapeutic agent within 4 week prior entry . Immunomodulating agent within 3 month prior entry . Prior Treatment : Excluded : Radiotherapy within 4 week prior entry . Risk Behavior : Excluded : Current alcohol illicit drug use may interfere patient 's ability comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>